Ophthalmologist

Publications

 

1. Twelve months of follow-up after intravitreal injection of
ranibizumab for the treatment of idiopathic parafoveal telangiectasia.
Rouvas A,Malamos P, Douvali M, Ntouraki A, Markomichelakis NN Clin Ophthalmol. 2013;7:1357-62.

2. Intravitreal ranibizumab for the treatment of inflammatory
choroidal neovascularization. Rouvas A, Petrou  P, Douvali M, Ntouraki
A, Vergados I, Georgalas I, Markomichelakis N Retina 2011 May;31(5):871-9.

3. Angiographic and OCT features of retinal angiomatous proliferation. Rouvas A, Papakostas TD, Ntouraki A, Douvali M, Vergados I, Ladas I Eye (Lond) 2010 Νοv;24(11):1633-42.

4. Photodynamic therapy, ranibizumab and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 2011 Mar;31(3):464-74.

5. Intravitreal ranibizumab (Lucentis) for branch retinal vein
occlusion induced macular edema: nine months results of a prospective
study.Rouvas A, Petrou P, Ntouraki A, Douvali M, Ladas I, Vergados I. Retina 2010 Jun;30(6):893-902.